---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-057691"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:50:44.453688+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma Q1 net revenue $26.0M (+126% YoY); net loss $141.4M on $92.4M LB54640 charge

## Summary
- Net product revenue $26.0M (Q1 2023: $11.5M); 74% from U.S. sales.
- Net loss $141.4M ($2.35/share) vs $52.2M ($0.92/share) prior year; R&D spend $128.7M incl $92.4M IPR&D for LB54640.
- Cash $201M at March 31; closed $150M preferred stock financing April 15 extending runway into 2026.
- On track to submit sNDA for IMCIVREE in pediatric patients 2 to <6 years old in Q2 2024.
- Phase 3 hypothalamic obesity trial top-line data expected H1 2025; Japanese cohort dosing starts Q2 2024.

## SEC filing metadata
- accession: 0001104659-24-057691
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465924057691/0001104659-24-057691-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465924057691/tm2413330d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-057691
- JSON: https://secwatch.observer/filing/0001104659-24-057691.json
- Plain text: https://secwatch.observer/filing/0001104659-24-057691.txt

## Key facts
- Earnings Releases
  RHYTHM PHARMACEUTICALS, INC. reported for the quarter ended March 31, 2024 results: revenue $26.0 million.
  - Period: for the quarter ended March 31, 2024
  - Revenue: $26.0 million
  - Result: reported results
  source text: Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update -- First quarter 2024 net revenue from global sales of IMCIVREE ® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 years old in approved indications in second quarter of 2024 -- -- Phase 3 trial
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000110465924057691/0001104659-24-057691-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.